Scrip World Pharmaceutical News

Scrip Intelligence (Scrip) is an English language international pharmaceutical news, analysis and data service. First published as a weekly print newsletter in March 1972, Scrip included articles on side-effects, regulatory changes and mergers and acquisitions. Scrip World Pharmaceutical News was initially published by advertising company J Walter Thomson but was bought by its e Dr Philip J Brown in 1976 for £2000, who founded PJB Publishing. Brown sold Scrip, associated titles and his company to Informa for £150 million in 2003.[1][2][3] Scrip has now developed into an online global pharma news and analysis service. It provides daily news and analysis on the biotechnology and pharmaceutical industry including areas such as policy & regulation, business news, research & development, generics, drug delivery, and clinical trials.

Scrip World Pharmaceutical News
TypeNews and analysis service
FormatDaily online
Owner(s)Informa plc (LSE: INF)
PublisherPhilip Jarvis
EditorMike Ward
FoundedMarch 1972
HeadquartersTelephone House
69-77 Paul St
London
EC2A 4LQ
England
Websitewww.scripnews.com

Scrip subscriber base

The Scrip readership has grown to over 100,000 worldwide,[4] half of which are in Europe. Scrip is read by managers and executives working across all disciplines in pharmaceutical and biotech companies worldwide.[5]

Editors
  • Barbara Obstoj (1972–76)
  • Philip Brown (1977–86)
  • Moira Dower (1986–96)
  • John Davis (1997-2007)
  • Alex Shimmings (2007-2010)
  • Mike Ward (2010–present)

Scrip editorial team

Scrip has a large independent editorial team of 21. The journalists are based throughout the world in Washington, D.C., Tokyo, India, and London to ensure a global emphasis to the latest news stories.

  • "Science desk" - The R&D section tracks the fortune of marketed and developmental drugs, from clinical data to their passage through the regulatory process.[6][7]
  • "Europe coverage" - Scrip's Europe based desk covers all the political and regulatory developments that affect the pharmaceutical industry in the 27 member states, other European countries and the Russian Federation.
  • "US coverage" - Scrip's US team details the political developments from Washington affecting the global pharma industry, such as U.S. Food and Drug Administration safety and regulatory matters, as well as litigation, Generics and pharmacy.[8]
  • "World coverage" - Scrip's locally based world coverage focuses on Japan and other Pacific Rim markets, Asia and Latin America.
  • "Business news" - Scrip's global reporters bring information on financial and business affairs in the pharma and biotech sectors.[9]
  • "Analyst team" - Scrip's analysts offer an insight into the industry's more significant developments.[10]
gollark: <@356107472269869058> <@356107472269869058> <@356107472269869058> <@356107472269869058> <@356107472269869058> <@356107472269869058> <@356107472269869058> readd epicbot.
gollark: [ED]
gollark: [REDACT]
gollark: Good luck synchronizing them!
gollark: Thus apiobees.

References
  1. Wray, Richard (2003-12-03). "£2,000 niche buy nets £150m for science journalist". The Guardian. ISSN 0261-3077. Retrieved 2016-10-12.
  2. "Three new Square fellows". Pharmaceutical Journal. Retrieved 2016-10-12.
  3. "Informa buys PJB Publications for £120m – Press Gazette". www.pressgazette.co.uk. Retrieved 2016-10-12.
  4. "Scrip's readership reaches over 100,000". scripnews.com. Retrieved 2008-08-04.
  5. "Scrip's readers are global mid-senior level management". scripnews.com. Retrieved 2008-08-04.
  6. "Research and development news". scripnews.com. Retrieved 2008-08-04.
  7. "Clinical trials news". scripnews.com. Retrieved 2008-08-04.
  8. "Policy and regulation news". scripnews.com. Retrieved 2008-08-04.
  9. "Financial news". scripnews.com. Retrieved 2008-08-04.
  10. "Scrip's analysis team". scripnews.com. Retrieved 2008-08-04.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.